Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities
- None.
- None.
Insights
Hoth's HT-001 shows promise for treating EGFR inhibitor skin toxicities, with interim Phase 2a data and patent protection advancing.
Hoth Therapeutics is developing HT-001, a novel topical treatment targeting an important unmet need in oncology supportive care: the skin toxicities caused by EGFR inhibitor cancer therapies. These side effects often force patients to reduce dosage or discontinue potentially life-saving treatments, creating a significant market opportunity within the
The upcoming KOL event will feature prominent experts sharing interim results from HT-001's Phase 2a trial. While specific efficacy metrics aren't disclosed yet, the press release indicates the preliminary data demonstrates both safety and efficacy in the open-label cohort. If successful, HT-001 could become standard prophylactic care prescribed alongside EGFR inhibitors.
The company has strategically strengthened its intellectual property position, receiving a USPTO filing receipt for HT-001's formulation. This patent protection is crucial for maintaining market exclusivity and maximizing commercial potential if the therapy proves successful in later-stage trials.
The focus on dermatological toxicities represents a targeted approach to improving cancer care outcomes. Rather than developing a new cancer treatment directly, Hoth is addressing a critical barrier to effective treatment – patient compliance and quality of life during therapy. This supportive care strategy may offer a faster path to market with potentially fewer regulatory hurdles than primary oncology treatments.
Company Expands IP Portfolio While Advancing Clinical Innovation in Oncology Supportive Care
Case Study and Interim Clinical Trial Results Will Be Discussed
These common treatment-limiting side effects—such as rash and inflammation—often force patients to reduce or stop potentially life-saving cancer therapy. HT-001 offers a targeted solution aimed at protecting patients' quality of life and ensuring continued access to their critical oncology treatments.
- The overall chemotherapy drug market was valued at
USD 10.87 billion in 2024 and is expected to reachUSD 18.35 billion by 2031. A significant portion of this market will involve patients who experience skin toxicities.* - Supportive care needs: The rise in chemotherapy treatments naturally drives demand for supportive care drugs to manage side effects, including skin rashes.*
- Unmet needs: While supportive care drugs exist, chemotherapy-induced skin rash, particularly conditions like Acral erythema (hand-foot syndrome), can be severe and debilitating, highlighting the potential for novel or improved treatment options.*
Robb Knie, CEO of Hoth Therapeutics, remarked "HT-001 Presents the first of its kind treatment for cancer patients suffering with skin toxicities associated with EGFR therapies. We are excited to present the groundbreaking case study and interim Phase 2a results. We believe our data highlights HT-001's strong safety profile and the potential for it to set a new standard of care in this underserved area."
The upcoming event will feature expert commentary from leading derm-oncology and dermatology specialists Jonathan Hale Zippin M.D., Ph.D. and Adam Friedman, M.D., F.A.A.D., who will highlight the urgent clinical need and the promising role of HT-001 in cancer care, including the preliminary data results showing safety and efficacy in the open-label cohort of the ongoing clinical trial for HT-001. Investors will gain an inside look at how HT-001 could reshape the treatment landscape for cancer-related dermatologic side effects and become a prophylactic treatment option used by oncologists prescribing EGFR inhibitors to patients.
In tandem with clinical momentum, Hoth recently received a USPTO Filing Receipt for a new patent application covering HT-001's unique formulation—further reinforcing its expanding intellectual property portfolio and strategic market protection for this asset.
Key Highlights:
- Addressing an unmet need with HT-001
- Strong IP strategy underway, expanding protection around HT-001
- Compelling mechanism of action to treat EGFR-inhibitor-induced toxicities
- Near-term clinical and development milestones to be discussed at the KOL event
The KOL event will also provide an update on Hoth's pipeline progress, IP strategy, and Phase 2 trial that is underway.
Investors, media, and potential partners along with healthcare professionals are invited to attend this event, information on how to join will be released as we near the event date, June 24, 2025, at 3:30PM EST.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of any health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, the company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-to-spotlight-ht-001-in-investor-focused-kol-event-addressing-breakthrough-combating-cancer-treatment-skin-toxicities-302474039.html
SOURCE Hoth Therapeutics, Inc.
FAQ
When is Hoth Therapeutics (HOTH) hosting its KOL event for HT-001?
What is the market potential for HT-001's target market according to Hoth Therapeutics?
Who are the key opinion leaders presenting at the HOTH event?
What is the purpose of Hoth Therapeutics' HT-001 treatment?
What recent intellectual property development has HOTH announced for HT-001?
